Oxford Biomedica trading update ignored as bid deadline looms

Oxford BioMedica reported 2025 revenue at the top end of guidance of £166-169m (≈30% growth) and full-year operating EBITDA of mid-to-high single-digit millions, with underlying EBITDA in low single-digit millions after stripping a one-off gain from its October US facility acquisition. Contracted client orders rose 20% to £224m and revenue backlog increased to £204m, while year-end cash was £96.9m (net cash £55.4m). Despite the solid trading update and divergent broker targets (Panmure 800p/1,050p EV/sales case; Peel Hunt 451p), shares fell ~9% as investors awaited a looming EQT put-up-or-shut-up takeover deadline on 25 February that is dominating sentiment.

Analysis

Market structure: The immediate winner is any arranger/acquirer (EQT or rival) able to secure OXB’s stable backlog (contracted orders £224m; revenue backlog £204m) and net cash (£55.4m) at scale; sellers and short-term liquidity providers lose if a control premium (>=800p implied by Panmure) is paid. The bid overhang has compressed free-float and amplified volatility: OXB traded ~600p pre-discussion, 708p today; absence of a bid risks a rapid reversion toward broker median (Peel 451p) or the pre-bid band, creating a multi-hundred-pence range in days.

Risk assessment: Immediate tail risk (next 24–72h) is EQT walking — price gap down >10–25% likely; medium-term (weeks–months) risk includes slower conversion of backlog and integration issues at Durham where a one-off gain inflated EBITDA, masking low single-digit underlying EBITDA. Hidden dependency: client concentration and conversion rates (how much of £204m converts to 2026 revenue) and potential regulatory/audit findings on the Durham facility that could force capex or write-offs.

Trade implications: Event-driven shorts or longs are time-sensitive. If a firm bid >=800p is announced, short-dated calls or buy-and-hedge shares capture upside; if no bid by 25 Feb close, initiate short/put exposure (expect 15–30% downside within 1–3 months). Pair trade idea: short OXB vs long diversified CDMO (NYSE:CTLT or SMI:LONN) to isolate M&A/idiosyncratic risk.

Contrarian angles: Consensus prices either a premium or a collapse; what’s missed is durable revenue visibility from backlog (£204m) and net cash that underpin a takeover valuation above pre-bid levels. If EQT walks, activist interest or rival bidders often surface within 3–6 months in this space — initial sell-offs can be overdone by 20–40% and create buy-on-dip opportunities for patient, event-driven allocators.

Key Decisions for Investors

• Establish a tactical 2% NAV long in OXB (LSE:OXB) via shares or 2–3 week 700p calls if a firm offer >=800p is announced; take profit at +20–30% or on deal completion (whichever first).
• If no firm bid by market close 25 Feb 2026, deploy a 1.5% NAV short/put trade: buy 1-month 650p puts or short shares size 1.5% NAV, target 15–30% downside in 1–3 months; tighten or stop out if OXB outperforms the CDMO index by >15%.
• Establish a relative-value pair: short OXB (1.5% NAV) vs long Catalent (NYSE:CTLT) or Lonza (SMI:LONN) (1.5% NAV) if bid walks; aim to capture idiosyncratic unwind over 3 months, exit if spread narrows <5% or widens >30%.
• If long OXB entering a post-bid premium, sell 10% OTM covered calls (3-month) to monetize volatility; if EQT announces exclusivity or diligence within 2 weeks, scale long to 3% NAV and hedge with 2% NAV 3-month puts to cap downside from failed bids.